2.12
前日終値:
$2.12
開ける:
$2.13
24時間の取引高:
62,017
Relative Volume:
0.96
時価総額:
$86.59M
収益:
$2.70M
当期純損益:
$5.53M
株価収益率:
19.27
EPS:
0.11
ネットキャッシュフロー:
$-10.55M
1週間 パフォーマンス:
-0.47%
1か月 パフォーマンス:
-0.47%
6か月 パフォーマンス:
-7.83%
1年 パフォーマンス:
-16.86%
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
名前
Oramed Pharmaceuticals Inc
セクター
電話
646-844-1164
住所
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
ORMP を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ORMP
Oramed Pharmaceuticals Inc
|
2.12 | 87.01M | 2.70M | 5.53M | -10.55M | 0.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-01-12 | ダウングレード | Canaccord Genuity | Buy → Hold |
2022-02-18 | 開始されました | Cantor Fitzgerald | Overweight |
2021-04-20 | 開始されました | Canaccord Genuity | Buy |
2021-02-09 | 開始されました | National Securities | Buy |
2020-12-03 | 開始されました | Alliance Global Partners | Buy |
2020-03-11 | 開始されました | Aegis Capital | Buy |
2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
2017-12-11 | 再開されました | B. Riley FBR, Inc. | Buy |
2016-05-26 | 繰り返されました | FBR Capital | Outperform |
2015-12-01 | 繰り返されました | H.C. Wainwright | Buy |
2015-11-19 | 開始されました | FBR Capital | Outperform |
2015-04-13 | 再開されました | MLV & Co | Buy |
2014-01-30 | 繰り返されました | Aegis Capital | Buy |
2014-01-08 | 繰り返されました | Aegis Capital | Buy |
2014-01-08 | 開始されました | MLV & Co | Buy |
2013-12-03 | 開始されました | Aegis Capital | Buy |
すべてを表示
Oramed Pharmaceuticals Inc (ORMP) 最新ニュース
What analysts say about Oramed Pharmaceuticals Inc. stockRapid profit acceleration - jammulinksnews.com
Oral Proteins & Peptides Market to Surge to US$24 Billion by 2030, Driven by Chronic Disease Burden and Drug Delivery Innovation - Barchart.com
Is Oramed Pharmaceuticals Inc. a good long term investmentPowerful market insights - jammulinksnews.com
What drives Oramed Pharmaceuticals Inc. stock priceRapid capital growth - jammulinksnews.com
Oramed Pharmaceuticals Inc. Stock Analysis and ForecastUnprecedented profit potential - Autocar Professional
What makes Oramed Pharmaceuticals Inc. stock price move sharplyFree Group Entry - Newser
Why Oramed Pharmaceuticals Inc. stock attracts strong analyst attentionRisk Managed Trading Strategy - Newser
How Oramed Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser
Head to Head Survey: Oramed Pharmaceuticals (NASDAQ:ORMP) and Smith & Nephew SNATS (NYSE:SNN) - Defense World
Alpha Tau Medical's $36.9M Financing: A Strategic Leap Toward Revolutionary Cancer Therapy - AInvest
Oramed Pharmaceuticals : Announces Xiaoming Gao Joins Board of Directors - marketscreener.com
Oral Biologics Market Outlook 2025: Rising Demand, Market Size, - openPR.com
Two Sigma Advisers LP Invests $662,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Oral Biologics Market in 2025-2032 Detailed Study Analysis with - openPR.com
Alpha Tau to Present at Jefferies Global Healthcare Conference - Stock Titan
Acusphere (OTCMKTS:ACUS) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average – Should You Sell? - Defense World
Oramed Pharm Extends Stock Buyback Program - TipRanks
Dimensional Fund Advisors LP Grows Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World
Oramed: Q1 Earnings Snapshot - New Haven Register
Alpha Tau Medical appoints new board member By Investing.com - Investing.com India
Alpha Tau Medical appoints new board member - Investing.com
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire
StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell - Defense World
Renaissance Technologies LLC Trims Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
LPL Financial LLC Sells 21,250 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Pharmaceuticals Inc (ORMP) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):